Zydus Lifesciences’ arm acquires 100% stake in FBC Medical
The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents
Zydus Lifesciences’ indirect wholly owned subsidiary -- Amplitude SAS (Amplitude) has acquired 100% share capital of FBC Medical, France, a simplified joint stock. The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents. By acquiring and integrating the FBC Medical, Amplitude expects to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs. The cost of the said acquisition is 700,000 euro.
Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
